Laboratories JUVISE Pharmaceuticals

What Laboratories JUVISE Pharmaceuticals does

Laboratories JUVISE Pharmaceuticals is a France-headquartered specialty pharmaceutical company that acquires established "princeps" (original) medications from major pharmaceutical groups divesting mature products, then ensures continued manufacturing, regulatory stewardship, and commercialization of those assets. Founded in 2008 by Frédéric Mascha in Villeurbanne (Lyon), the company has assembled a portfolio of approximately 10 princeps medicines across five therapeutic areas: multiple sclerosis, gastroenterology, oncology, cardiology, and rheumatology. Its largest asset is Ponvory® (ponesimod), acquired from Johnson & Johnson in March 2024 with rights covering all markets outside the US and Canada and patent protection through 2035; Ponvory alone accounts for roughly 24% of FY2024 expected revenue of approximately €180M. Other portfolio brands include Arimidex® and Casodex® (oncology, ex-AstraZeneca), Pylera® (gastroenterology, ex-AbbVie), and Esidrex®, Sintrom®, and Digoxine-Juvisé® (cardiology, ex-Novartis).

The company's operating model is asset-light and network-based: approximately 60 professionals between Paris and Lyon orchestrate 18 finished-product manufacturing sites and 12 active pharmaceutical ingredient partners, with commercialization executed via distributors, Contract Sales Organizations (CSOs), and commercial partners across 80 countries on five continents. Products are marketed through medical affairs and field sales channels targeting healthcare professionals, with 63% of FY2023 sales generated in Europe (particularly France, Germany, Italy, UK, Spain, and Portugal) and the balance in Africa, the Middle East, and Asia. Manufacturing is intentionally concentrated in Europe — 81% in Europe and 51% in France as of 2023, with a stated target of nearly 100% European production by end of 2024 — reflecting both regulatory reliability and supply-chain resilience considerations.

Juvisé generates revenue primarily through pharmaceutical product sales of acquired brands and earns licensing/commercialization income from its territorial agreements with divesting originators such as Novartis, AstraZeneca, AbbVie, and Johnson & Johnson. Following the March 2024 Ponvory® transaction, the company opened its capital to Bpifrance (French sovereign fund) and Pemberton Asset Management (European private credit manager), who acquired minority stakes alongside Société Générale's continued banking role. The family-owned business remains controlled by founder Frédéric Mascha and targets roughly 2.5 million patients annually with 4 of its medicines on the WHO Essential Medicines List.

Name

Laboratories JUVISE Pharmaceuticals

Legal name

Laboratoires Juvisé Pharmaceuticals

Website

https://juvisepharmaceuticals.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Laboratories JUVISE Pharmaceuticals is a French specialty pharmaceutical company that acquires and commercializes established "princeps" medications from major pharmaceutical groups across multiple sclerosis, oncology, cardiology, gastroenterology, and rheumatology, distributing through a partner-led network to 80 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Specialty pharmaceuticals
• Essential medicines
• Pharmaceutical licensing
• Drug commercialization
• Princeps medications

Headquarters

HQ city

Villeurbanne

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical product sales: Juvisé Pharmaceuticals generates revenue through the acquisition and commercialization of established pharmaceutical drugs (princeps medications). The company acquires rights to mature drugs from large pharmaceutical companies, relocates manufacturing to Europe, and commercializes them through its distribution network. Revenue in 2024 expected to reach approximately 180M€ (+38% vs 2023), with PONVORY® accounting for about 24% of revenues.
2. Licensing and distribution partnerships: The company enters into licensing agreements with major pharmaceutical companies (Novartis, AstraZeneca, AbbVie, J&J) to commercialize their divested products in specific territories, earning revenue through product sales and commercialization fees.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Juvisé Pharmaceuticals acquires the global commercial rights (excluding certain territories) to mature, high-value essential medicines (princeps) from large originator pharmaceutical companies such as Novartis, AstraZeneca, AbbVie, and Johnson & Johnson, then manufactures them via a network of approximately 30 partner sites and commercializes them across around 80 countries through its own medical affairs, marketing, and distribution capabilities. The portfolio of 10 princeps medications spans multiple sclerosis, gastroenterology, oncology, cardiology, rheumatology, and neuropsychiatry, and treats approximately 2.5 million patients per year.

Product overview

JUVISE Pharmaceuticals operates as a specialty pharmaceutical company focused on essential medicines. The company acquires established princeps (original) medications from large pharmaceutical companies and ensures their continued production, distribution, and marketing. Their portfolio comprises 10 medicines across five therapeutic areas: Neuroscience (multiple sclerosis, neuropsychiatry), Gastroenterology (H. pylori treatment), Oncology (breast and prostate cancer), Cardiology (anticoagulation, hypertension, heart failure), and Rheumatology (muscular contractures). The products are commercialized in approximately 80 countries, with focus on European markets including France, Germany, Italy, UK, Spain, and Portugal.

Differentiator

Problem solved

Functional benefit

Products and services

• Ponvory® (ponesimod) First-line oral disease-modifying treatment for adults with active forms of relapsing multiple sclerosis (RMS); demonstrated a 30.5% reduction in Annualized Relapse Rate versus teriflunomide in the OPTIMUM Phase III study. Commercialized by Juvisé outside the US and Canada; protected by patents, the latest of which expires in 2035.
• Arimidex® (anastrozole) Aromatase inhibitor indicated for the treatment of breast cancer in postmenopausal women; acquired from AstraZeneca in 2019 and part of Juvisé's oncology portfolio.
• Casodex® (bicalutamide) Anti-androgen medication indicated for the treatment of prostate cancer; acquired from AstraZeneca in 2019.
• Pylera® (bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride) Combination therapy for the eradication of Helicobacter pylori and prevention of peptic ulcer recurrence; acquired from AbbVie in 2022 and successfully relaunched in Europe in 2023, with MHRA marketing authorization in the UK granted in March 2024.
• Esidrex® (hydrochlorothiazide) Thiazide diuretic for the treatment of oedema of cardiac, renal, or hepatic origin and for arterial hypertension; acquired from Novartis in 2016.
• Sintrom® (acenocoumarol) Vitamin K antagonist anticoagulant for the treatment and prevention of thromboembolic disorders; acquired from Novartis in 2016 and subsequently granted marketing authorizations in Vietnam (2024) and Mali (2023).
• Digoxine-Juvisé® (digoxin) Cardiac glycoside indicated for the treatment of heart failure and certain arrhythmias; acquired from Novartis in 2016 and relaunched under the Digoxine-Juvisé® brand.
• Lumirelax® (methocarbamol) Centrally acting muscle relaxant for the adjunctive treatment of painful muscular contractures in rheumatology; acquired from Thera France in 2009 and subsequently granted marketing authorizations in Senegal (2020) and Morocco (2023).
• Insidon® (opipramol) Tricyclic antidepressant used in the treatment of depression and anxiety disorders; acquired from Thera France in 2011.
• Entumin® (clotiapine) Antipsychotic medication indicated for the treatment of schizophrenia; acquired from Novartis in 2011.
• Extovyl® Acquired by Juvisé Pharmaceuticals from Thera France in 2009 as part of the company's initial portfolio of essential medicines.
• Calmixène® Acquired by Juvisé Pharmaceuticals from Thera France in 2011 as part of its portfolio of essential mature medicines.
• Proxeed Plus® In-licensed by Juvisé Pharmaceuticals from Sigma-Tau in 2013 for distribution within its specialty pharmaceutical portfolio.
• Ezerex® In-licensed by Juvisé Pharmaceuticals from Sigma-Tau in 2013 for distribution within its specialty pharmaceutical portfolio.

Quantifiable outcome

• Ponvory® demonstrated 30.5% reduction in Annualized Relapse Rate compared to teriflunomide in OPTIMUM Phase III study
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Actelion Pharmaceuticals Ltd (Johnson & Johnson)coreOEM/ Whitelabel/ Licensing Partner · 26 March 2024Juvisé acquired global commercial rights (excluding US and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company. Ponvory® is indicated for treatment of adults with active forms of relapsing multiple sclerosis. Juvisé will assume worldwide manufacturing duties from sites in France and Switzerland.
• LazardminorOthers · 26 March 2024Lazard acted as financial advisor to Juvisé Pharmaceuticals and its shareholders for the Ponvory® acquisition transaction.
• AbbViecoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Juvisé acquired Pylera® from AbbVie for the treatment of H. pylori infection. Pylera® was successfully relaunched in Europe in 2023.
• AstraZenecacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2019Juvisé acquired Arimidex® (anastrozole) and Casodex® (bicalutamide) from AstraZeneca, expanding its oncology portfolio.
• NovartiscoreOEM/ Whitelabel/ Licensing Partner · 1 January 2011Juvisé acquired multiple products from Novartis including Entumin® (2011), Esidrex® (2016), Sintrom® (2016), and Digoxine-Juvisé® (2016).

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Aspen Pharmacare: South African specialty pharma that grew largely by acquiring mature brands divested by Big Pharma and commercializing them across emerging and developed markets — directly analogous thesis and counterparty mix to Juvisé.
• Almirall: Spanish specialty pharma with a similar model of acquiring or licensing established molecules and commercializing them across European and international markets through focused sales infrastructure.
• Stada Arzneimittel: German specialty and generics group operating a network-based model with broad European distribution and a portfolio of mature, established brands — strong comparability on product mix and pan-European commercial strategy.
• H. Lundbeck: Danish specialty pharma with concentrated CNS/neuroscience therapeutic focus — closely comparable to Juvisé's MS and neuropsychiatry franchise on therapeutic area overlap and European specialty commercial approach.
• Vifor Pharma: Swiss specialty pharma with comparable model of in-licensing and commercializing established specialty medicines across European and international markets, now part of CSL but historically run as a focused mid-cap specialty player.
• Recordati: Italian specialty pharmaceutical group that acquires, develops, and markets mature branded drugs across Europe and international markets — directly comparable business model to Juvisé, including mid-size pharma M&A and European commercial focus.
• Ipsen: French-headquartered specialty pharmaceutical company with comparable European footprint and focus on specialty therapeutic areas (oncology, neuroscience, rare diseases). More R&D-intensive but most culturally and operationally comparable domestic peer.
• Zentiva: European specialty and generics company with strong presence in France, Germany, Italy, Spain, and CEE markets — comparable European footprint, branded-generic product mix, and private-equity-backed growth model.

Regional players

• Hikma Pharmaceuticals: MENA-headquartered specialty and generics pharma with significant European operations through Hikma Europe — comparable diversified branded/specialty portfolio model, though larger and broader in scope than Juvisé.

Emerging players

• Neuraxpharm: European CNS specialty pharma that acquires, in-licenses, and commercializes established neurology and psychiatry products — directly comparable on therapeutic area (CNS, neuropsychiatry) and European mid-market specialty focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/juvise-pharmaceuticals

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratories JUVISE Pharmaceuticals